

WHO DRUG INFORMATION

Contents

General Policy Topics

- Postmarketing surveillance:
what is being achieved? 95

Personal Perspectives

- Pharmaceutical Inspection Convention 96

Reports on Individual Drugs

- Control of *Ascaris lumbricoides*: selective
or community therapy? 98
Ofloxacin: promise as an anti-leprosy agent 99
Opioids for chronic pain? 99
Spermicides and sexually transmitted diseases 100
Pralidoxime: is it really of value in
organophosphorus poisoning? 101
Rubella immunization prevention policies 102
Herbal medicines: need for regulatory
oversight 103
Vitamin D fortification: the case for
quantitative monitoring 103
Ritodrine: does it really prevent preterm
labour? 104

General Information

- Drug Information Centres 106
Expensive drugs and cost containment 106
Parental attitudes towards children's
medicines: a case study 108

Regulatory Matters

- "First-dose" anaphylactoid reactions 110
Fenfluramines and pulmonary hypertension 110

- Fluoxetine: association with suicide
remains unconfirmed 110
Growth hormone and Creutzfeldt-Jacob
disease 111
Sumatriptan contraindicated in patients with
ischaemic heart disease 111
Terafloxacin: unacceptable incidence of
serious adverse effects 112
Tibolone and vaginal bleeding 112
Triazolam, anxiety and amnesia 112

Essential Drugs

- Diseases of the skin (*continued*) 113
Benzoyl peroxide 121
Calamine lotion 121
Chlorphenamine 121
Dapsone 122
Dithranol 123
Erythromycin 123
Etretinate 124
Hydrocortisone 124
Methoxsalen 125
Prednisolone 126
Selenium sulfide 127
Sunscreens 128
Tar products 128
Tetracycline 129

Recent Publications

- The case for self-sufficiency in drug control 131

Recommended International Non-proprietary Names: List 32

133